Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

UCSF Chimera—A visualization system for exploratory research and analysis

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,260 · see citing works

[20] Processing of X-ray diffraction data collected in oscillation mode

Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · see citing works

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works

<i>PHENIX</i> : a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · see citing works

<i>Phaser</i> crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works

NMRPipe: A multidimensional spectral processing system based on UNIX pipes

Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,994 · see citing works

Inference of macromolecular assemblies from crystalline state.

Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,189 · see citing works

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · see citing works

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkòczi, G., Chen, V. B., Davis, I., Echols, N., Headd, J. J., Hung, L., Kapral, G. J., Grosse‐Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334 · see citing works

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · see citing works

New tools for automated high-resolution cryo-EM structure determination in RELION-3

Zivanov, J., Nakane, T., Forsberg, B., Kimanius, D., Hagen, W., Lindahl, E., & Scheres, S. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,377 · see citing works

GISAID: Global initiative on sharing all influenza data – from vision to reality

Shu, Y., & McCauley, J. (2017) · Eurosurveillance · doi:10.2807/1560-7917.es.2017.22.13.30494 · Cited by 3,039 · see citing works

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

Kissler, S. M., Tedijanto, C., Goldstein, E., Grad, Y. H., & Lipsitch, M. (2020) · Science · doi:10.1126/science.abb5793 · Cited by 2,611 · see citing works

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535 · see citing works

Detection of a SARS-CoV-2 variant of concern in South Africa

Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510 · see citing works

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · doi:10.1101/2021.01.25.428137 · Cited by 2,328

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works

Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding

Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · see citing works

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · see citing works

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853 · see citing works

Automated molecular microscopy: The new Leginon system

Suloway, C. J. M., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J. D., Stagg, S. M., Potter, C. S., & Carragher, B. O. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.03.010 · Cited by 1,681 · see citing works

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2380-z · Cited by 1,667 · see citing works

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599 · see citing works

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., So, R. T. Y., Lv, H., Mok, C. K. P., & Wilson, I. A. (2020) · Science · doi:10.1126/science.abb7269 · Cited by 1,405 · see citing works

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · see citing works

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385 · see citing works

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353 · see citing works

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349 · see citing works

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343 · see citing works

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · see citing works

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303 · see citing works

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286 · see citing works

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246 · see citing works

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Rogers, T. F., Zhao, F., Huang, D., Beutler, N., Burns, A., He, W.-T., Limbo, O., Smith, C., Song, G., Woehl, J., et al. (2020) · Science · doi:10.1126/science.abc7520 · Cited by 1,230 · see citing works

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210 · see citing works

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells

Cao, Y., Su, B., Guo, X., Sun, W., Deng, Y., Bao, L., Zhu, Q., Zhang, X., Zheng, Y., Geng, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.025 · Cited by 1,188 · see citing works

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · see citing works

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178 · see citing works

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01285-x · Cited by 1,147 · see citing works

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140 · see citing works

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Greaney, A. J., Starr, T. N., Gilchuk, P., Zost, S. J., Binshtein, E., Loes, A. N., Hilton, S. K., Huddleston, J., Eguia, R., Crawford, K. H. D., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2020.11.007 · Cited by 1,016 · see citing works

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.037 · Cited by 992 · see citing works

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Wu, Y., Wang, F., Shen, C., Peng, W., Li, D., Zhao, C., Li, Z., Li, S., Bi, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc2241 · Cited by 955 · see citing works

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

Menachery, V. D., Yount, B. L., Debbink, K. M., Agnihothram, S., Gralinski, L. E., Plante, J. A., Graham, R. L., Scobey, T., Ge, X., Donaldson, E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3985 · Cited by 901 · see citing works

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B. F., Hahn, A. S., Krüger, N., Graichen, L., Hofmann-Winkler, H., Kempf, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.036 · Cited by 897 · see citing works

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881 · see citing works

Appion: An integrated, database-driven pipeline to facilitate EM image processing

Lander, G. C., Stagg, S. M., Voss, N. R., Cheng, A., Fellmann, D., Pulokas, J., Yoshioka, C., Irving, C., Mulder, A. M., Lau, P., et al. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.01.002 · Cited by 836 · see citing works

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Jongeneelen, M. A. C., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Brandenburg, B., et al. (2011) · Science · doi:10.1126/science.1204839 · Cited by 823 · see citing works

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795 · see citing works

SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697 · see citing works

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03471-w · Cited by 651 · see citing works

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636 · see citing works

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera

Xie, X., Liu, Y., Liu, J., Zhang, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01270-4 · Cited by 628 · see citing works

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625 · see citing works

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625 · see citing works

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00628-0 · Cited by 603 · see citing works

Structural basis of a shared antibody response to SARS-CoV-2

Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., et al. (2020) · Science · doi:10.1126/science.abd2321 · Cited by 589 · see citing works

Antibody evasion by the P.1 strain of SARS-CoV-2

Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583 · see citing works

DoG Picker and TiltPicker: Software tools to facilitate particle selection in single particle electron microscopy

Voss, N. R., Yoshioka, C., Radermacher, M., Potter, C. S., & Carragher, B. O. (2009) · Journal of Structural Biology · doi:10.1016/j.jsb.2009.01.004 · Cited by 571 · see citing works

A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · doi:10.1101/2021.02.05.21251182 · Cited by 559 · see citing works

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · see citing works

Neutralizing Activity of BNT162b2-Elicited Serum

Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537 · see citing works

Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510 · see citing works

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape

Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 495 · see citing works

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Zost, S. J., Gilchuk, P., Chen, R. E., Case, J. B., Reidy, J. X., Trivette, A., Nargi, R. S., Sutton, R. E., Suryadevara, N., Chen, E. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0998-x · Cited by 423 · see citing works

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103154118 · Cited by 421 · see citing works

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Wu, K., Werner, A. P., Moliva, J. I., Koch, M., Choi, A., Stewart-Jones, G. B. E., Bennett, H., Boyoglu-Barnum, S., Shi, W., Graham, B. S., et al. (2021) · doi:10.1101/2021.01.25.427948 · Cited by 419 · see citing works

SARS-like WIV1-CoV poised for human emergence

Menachery, V. D., Yount, B. L., Sims, A. C., Debbink, K., Agnihothram, S. S., Gralinski, L. E., Graham, R. L., Scobey, T., Plante, J. A., Royal, S. R., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517719113 · Cited by 418 · see citing works

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Wu, K., Werner, A. P., Koch, M., Choi, A., Narayanan, E., Stewart-Jones, G. B. E., Colpitts, T., Bennett, H., Boyoglu-Barnum, S., Shi, W., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102179 · Cited by 409 · see citing works

CoV-AbDab: the coronavirus antibody database

Raybould, M. I. J., Kovaltsuk, A., Marks, C., & Deane, C. M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa739 · Cited by 383 · see citing works

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines

Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Sanders, K. O., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.03.002 · Cited by 378 · see citing works

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Dejnirattisai, W., Zhou, D., Ginn, H. M., Duyvesteyn, H. M. E., Supasa, P., Case, J. B., Zhao, Y., Walter, T. S., Mentzer, A. J., Liu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.032 · Cited by 371 · see citing works

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.001 · Cited by 364 · see citing works

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model

Kreye, J., Reincke, S. M., Kornau, H.-C., Sánchez-Sendin, E., Corman, V. M., Liu, H., Yuan, M., Wu, N. C., Zhu, X., Lee, C.-C. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.049 · Cited by 347 · see citing works

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus

Hedestam, G. B. K., Fouchier, R. A. M., Phogat, S. K., Burton, D. R., Sodroski, J., & Wyatt, R. T. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1819 · Cited by 340 · see citing works

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., et al. (2020) · Science · doi:10.1126/science.abe1502 · Cited by 336 · see citing works

In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K. J., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.021 · Cited by 331 · see citing works

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Kreer, C., Zehner, M., Weber, T., Ercanoglu, M. S., Gieselmann, L., Rohde, C., Halwe, S., Korenkov, M., Schommers, P., Vanshylla, K., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.044 · Cited by 313 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

Eguia, R., Crawford, K. H. D., Stevens-Ayers, T., Kelnhofer-Millevolte, L., Greninger, A. L., Englund, J. A., Boeckh, M. J., & Bloom, J. D. (2020) · doi:10.1101/2020.12.17.423313 · Cited by 258 · see citing works

A human coronavirus evolves antigenically to escape antibody immunity

(2021) · doi:10.1371/journal.ppat.1009453 · Cited by 258 · see citing works

Potent human neutralizing antibodies elicited by SARS-CoV-2 infectionPreprint

Ju, B., Zhang, Q., Ge, X., et al. (2020) · bioRxiv · doi:10.1101/2020.03.21.990770 · Cited by 256 · see citing works

Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Yadav, P. D., Sapkal, G. N., Abraham, P., Ella, R., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Gupta, N., Sahay, R. R., Shete, A. M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab411 · Cited by 251 · see citing works

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240 · see citing works

Individual Variation in the Germline Ig Gene Repertoire Inferred from Variable Region Gene Rearrangements

Boyd, S. D., Gaëta, B. A., Jackson, K., Fire, A. Z., Marshall, E. L., Merker, J. D., Maniar, J. M., Zhang, L. N., Sahaf, B., Jones, C. D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000445 · Cited by 238 · see citing works

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Du, S., Cao, Y., Zhu, Q., Yü, P., Qi, F., Wang, G., Du, X., Bao, L., Deng, W., Zhu, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.035 · Cited by 238 · see citing works

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant

Edara, V. V., Norwood, C., Floyd, K., Lai, L., Davis-Gardner, M. E., Hudson, W. H., Mantus, G., Nyhoff, L. E., Adelman, M. W., Fineman, R., et al. (2021) · Cell Host &amp; Microbe · doi:10.1016/j.chom.2021.03.009 · Cited by 224 · see citing works

Acquisition of the L452R Mutation in the ACE2-Binding Interface of Spike Protein Triggers Recent Massive Expansion of SARS-CoV-2 Variants

Tchesnokova, V. L., Kulasekara, H. D., Larson, L., Bowers, V., Rechkina, E., Kisiela, D., Sledneva, Y., Choudhury, D., Maslova, I., Deng, K., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00921-21 · Cited by 210 · see citing works

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Wang, L., Zhou, T., Zhang, Y., Yang, E. S., Schramm, C. A., Shi, W., Pegu, A., Oloniniyi, O. K., Henry, A. R., Darko, S. W., et al. (2021) · Science · doi:10.1126/science.abh1766 · Cited by 191 · see citing works

SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Brusic, V., Choudhary, M. C., Regan, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.027 · Cited by 189 · see citing works

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies

Yuan, M., Liu, H., Wu, N. C., & Wilson, I. A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.012 · Cited by 181 · see citing works

Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies

Zhu, X. Q., Mannar, D., Srivastava, S. S., Berezuk, A., Demers, J., Saville, J. W., Leopold, K., Li, W., Dimitrov, D. S., Tuttle, K. S., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001237 · Cited by 176 · see citing works

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

Hurlburt, N. K., Seydoux, E., Wan, Y.-H., Edara, V. V., Stuart, A. B., Feng, J., Suthar, M. S., McGuire, A. T., Stamatatos, L., & Pancera, M. (2020) · Nature Communications · doi:10.1038/s41467-020-19231-9 · Cited by 162 · see citing works

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

Wu, N. C., Yuan, M., Liu, H., Lee, C.-C. D., Zhu, X., Bangaru, S., Torres, J. L., Caniels, T. G., Brouwer, P. J. M., van Gils, M. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108274 · Cited by 157 · see citing works

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Ge, J., Wang, R., Ju, B., Zhang, Q., Sun, J., Chen, P., Zhang, S., Tian, Y., Shan, S., Cheng, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20501-9 · Cited by 157 · see citing works

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

Wan, J., Xing, S., Ding, L., Wang, Y., Gu, C., Wu, Y., Rong, B., Li, C., Wang, S., Chen, K., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107918 · Cited by 152 · see citing works

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143 · see citing works

Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD

Zhou, Y., Liu, Z., Li, S. N., Xu, W., Zhang, Q., da Silva, I. T., Li, C., Wu, Y., Jiang, Q., Liu, Z., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108699 · Cited by 134 · see citing works

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)

Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B. E., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104192 · Cited by 128 · see citing works

Theory of Equilibrium Binding of Symmetric Bivalent Haptens to Cell Surface Antibody: Application to Histamine Release from Basophils

Dembo, M., & Goldstein, B. (1978) · The Journal of Immunology · doi:10.4049/jimmunol.121.1.345 · Cited by 123 · see citing works

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Noy-Porat, T., Makdasi, E., Alcalay, R., Mechaly, A., Levy, Y., Bercovich-Kinori, A., Zauberman, A., Tamir, H., Yahalom-Ronen, Y., Israeli, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18159-4 · Cited by 122 · see citing works

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Hu, J., Peng, P., Wang, K., Fang, L., Luo, F.-Y., Jin, A.-S., Liu, B., Tang, N., & Huang, A. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00648-1 · Cited by 111 · see citing works

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Guo, Y., Huang, L., Zhang, G., Yao, Y., Zhou, H., Shěn, S., Shen, B., Li, B., Li, X., Zhang, Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22926-2 · Cited by 93 · see citing works

Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection

Yao, H., Sun, Y., Deng, Y.-Q., Wang, N., Tan, Y., Zhang, N.-N., Li, X.-F., Kong, C., Xu, Y.-P., Chen, Q., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00444-y · Cited by 87 · see citing works

Repertoire Builder: high-throughput structural modeling of B and T cell receptors

Dimitri, S., Li, S., Rozewicki, J., Katoh, K., Yamashita, K., Volkmuth, W., Cavet, G., & Standley, D. M. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00020h · Cited by 67 · see citing works

Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions

Shiakolas, A. R., Kramer, K. J., Wrapp, D., Richardson, S., Schäfer, A., Wall, S. J., Wang, N.-S., Janowska, K., Pilewski, K. A., Venkat, R., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100313 · Cited by 65 · see citing works

The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primatesPreprint

Li, D.-P., Edwards, R., Manne, K., Martinez, D. R., Schäfer, A., Alam, S., Wiehe, K., Lu, X.-Z., Parks, R., Sutherland, L. L., et al. (2021) · bioRxiv · doi:10.1101/2020.12.31.424729 · Cited by 62 · see citing works

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class

Rapp, M., Guo, Y., Reddem, E. R., Yu, J., Liu, L., Wang, P., Cerutti, G., Katsamba, P. S., Bimela, J. S., Bahna, F. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108950 · Cited by 58 · see citing works

Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies

Cerutti, G., Rapp, M., Guo, Y., Bahna, F. A., Bimela, J. S., Reddem, E. R., Yu, J., Wang, P., Liu, L., Huang, Y., et al. (2021) · Structure · doi:10.1016/j.str.2021.05.014 · Cited by 58 · see citing works

Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses

Banach, B. B., Cerutti, G., Fahad, A. S., Shen, C., de Souza, M. O., Katsamba, P. S., Tsybovsky, Y., Wang, P., Nair, M. S., Huang, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2021.109771 · Cited by 56 · see citing works

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors

Mor, M., Werbner, M., Alter, J., Safra, M., Chomsky, E., Lee, J. C., Hada-Neeman, S., Polonsky, K., Nowell, C., Clark, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009165 · Cited by 47 · see citing works

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Liu, H., Yuan, M., Huang, D.-L., Bangaru, S., Zhao, F.-Z., Lee, C. D., Peng, L., Barman, S., Zhu, X.-Y., Nemazee, D., et al. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 46 · see citing works

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Liu, H., Wu, N. C., Yuan, M., Bangaru, S., Torres, J., Caniels, T., van Schooten, J., Zhu, X.-Y., Lee, C. D., Brouwer, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.10.023 · Cited by 39 · see citing works

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2

Han, X., Wang, Y., Li, S., Hu, C., Li, T., Gu, C., Wang, K., Shen, M., Wang, J., Hu, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653189 · Cited by 31 · see citing works

Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2Preprint

Clark, S. A., Clark, L. E., Pan, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.13.381533 · Cited by 27 · see citing works

Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses

Bullen, G., Galson, J., Hall, G., Villar, P., Moreels, L., Ledsgaard, L., Mattiuzzo, G., Bentley, E., Masters, E. W., Tang, D. M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.678570 · Cited by 24 · see citing works

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Liu, H., Yuan, M., Huang, D.-L., Bangaru, S., Lee, C. D., Peng, L., Zhu, X.-Y., Nemazee, D., van Gils, M. V., Sanders, R., et al. (2021) · bioRxiv · doi:10.1101/2021.02.11.430866 · Cited by 24

Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody classPreprint

Rapp, M., Guo, Y., Reddem, E. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.11.426218 · Cited by 11 · see citing works

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functionsPreprint

Shiakolas, A. R., Kramer, K. J., Wrapp, D., Richardson, S., Schäfer, A., Wall, S. J., Wang, N.-S., Janowska, K., Pilewski, K. A., Venkat, R., et al. (2020) · bioRxiv · doi:10.1101/2020.12.20.414748 · Cited by 5 · see citing works

Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergencePreprint

Bullen, G., Galson, J., Villar, P., Moreels, L., Ledsgaard, L., Mattiuzzo, G., Hall, G., Bentley, E., Masters, E. W., Tang, D. M., et al. (2020) · bioRxiv · doi:10.1101/2020.12.29.424711 · Cited by 4 · see citing works

SARS-CoV-2 escape <i>in vitro</i> from a highly neutralizing COVID-19 convalescent plasma

Andreano, E., Piccini, G., Licastro, D., Casalino, L., Johnson, N. V., Paciello, I., Monego, S. D., Pantano, E., Manganaro, N., Manenti, A., et al. (2020) · doi:10.1101/2020.12.28.424451

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., et al. (2021) · doi:10.1101/2021.01.18.427166

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,288 · see citing works

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535 · see citing works

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433 · see citing works

Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron

Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.019 · Cited by 406 · see citing works

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Hastie, K. M., Li, H., Bedinger, D., Schendel, S. L., Dennison, S. M., Li, K., Rayaprolu, V., Yu, X., Mann, C. J., Zandonatti, M. A., et al. (2021) · Science · doi:10.1126/science.abh2315 · Cited by 299 · see citing works

Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution

Starr, T. N., Greaney, A. J., Hannon, W. W., Loes, A. N., Hauser, K., Dillen, J., Ferri, E., Farrell, A. G., Dadonaite, B., McCallum, M., et al. (2022) · bioRxiv · doi:10.1126/science.abo7896 · Cited by 282 · see citing works

Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant

Zhang, J., Xiao, T., Cai, Y., Lavine, C. L., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., Mayer, M. L., et al. (2021) · Science · doi:10.1126/science.abl9463 · Cited by 281 · see citing works

The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages

Martin, D. P., Weaver, S., Tegally, H., San, J. E., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.003 · Cited by 272 · see citing works

Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 273 · see citing works

Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody

Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., et al. (2022) · Science · doi:10.1126/science.abn8863 · Cited by 281 · see citing works

ScanNet: an interpretable geometric deep learning model for structure-based protein binding site prediction

Tubiana, J., Schneidman-Duhovny, D., & Wolfson, H. J. (2022) · Nature Methods · doi:10.1038/s41592-022-01490-7 · Cited by 274 · see citing works

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.003 · Cited by 240 · see citing works

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Hwang, Y., Lu, R., Su, S.-C., Chiang, P.-Y., Ko, S.-H., Ke, F.-Y., Liang, K.-H., Hsieh, T.-Y., & Wu, H. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-021-00784-w · Cited by 236 · see citing works

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227 · see citing works

A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection

Zhou, P.-P., Yuan, M., Song, G., Beutler, N., Shaabani, N., Huang, D.-L., He, W.-T., Zhu, X.-Y., Callaghan, S., Yong, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9215 · Cited by 132 · see citing works

Molecular basis of receptor binding and antibody neutralization of Omicron

Qin, H., Han, W., Li, J., Xu, S., Wang, Y., Xu, C., Li, Z., Wang, Y., Zhang, C., Huang, Z. W., et al. (2022) · Nature · doi:10.1038/s41586-022-04581-9 · Cited by 196 · see citing works

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Laffeber, C., de Koning, K., Kanaar, R., & Lebbink, J. H. G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167058 · Cited by 190 · see citing works

Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies

Wang, Y., Liu, C., Zhang, C., Wang, Y., Qin, H., Xu, S., Li, Z., Yang, Y. P., Huang, Z. W., & Cong, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-28528-w · Cited by 169 · see citing works

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

Wang, K., Jia, Z., Bao, L., Wang, L., Cao, L., Chi, H., Hu, Y., Li, Q., Zhou, Y., Jiang, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04466-x · Cited by 178 · see citing works

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination

Schaefer-Babajew, D. J., Wang, Z., Muecksch, F., Cho, A., Loewe, M., Cipolla, M., Raspe, R., Johnson, B. A., Canis, M., DaSilva, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05609-w · Cited by 161 · see citing works

Antiviral neutralizing antibodies: from in vitro to in vivo activity

Burton, D. R. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00858-w · Cited by 152 · see citing works

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease

Zhou, P.-P., Song, G., Liu, H., Yuan, M., He, W., Beutler, N., Zhu, X., Tse, L. V., Martinez, D. R., Schäfer, A., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.02.005 · Cited by 151 · see citing works

Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines

Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 148 · see citing works

Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses

Tas, J., Koo, J.-H., Lin, Y.-C., Xie, Z., Steichen, J., Jackson, A., Hauser, B., Wang, X., Cottrell, C., Torres, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.07.020 · Cited by 142 · see citing works

Mapping SARS-CoV-2 antigenic relationships and serological responses

Wilks, S. H., Mühlemann, B., Shen, X., Türeli, S., LeGresley, E. B., Netzl, A., Caniza, M. A., Chacaltana-Huarcaya, J. N., Corman, V. M., Daniell, X. G., et al. (2023) · Science · doi:10.1126/science.adj0070 · Cited by 134 · see citing works

Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice

Pymm, P., Adair, A., Chan, L., Cooney, J. P., Mordant, F., Allison, C., Lopez, E., Haycroft, E., O, Neill, M., et al. (2021) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.2101918118 · Cited by 134 · see citing works

Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection

Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N. E., & Walker, L. M. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq3511 · Cited by 131 · see citing works

mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants

Sokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.011 · Cited by 128 · see citing works

Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2

Zhang, Q., Ju, B., Ge, J., Chan, J. F., Cheng, L., Wang, R., Huang, W., Fang, M., Chen, P., Zhou, B., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24514-w · Cited by 112 · see citing works

Disease diagnostics using machine learning of B cell and T cell receptor sequences

Zaslavsky, M., Craig, E., Michuda, J., Sehgal, N., Ram-Mohan, N., Lee, J.-Y., Nguyen, K. D., Hoh, R. A., Pham, T. D., Röltgen, K., et al. (2025) · Science · doi:10.1126/science.adp2407 · Cited by 123 · see citing works

Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S‐glycoprotein, infectivity, re‐infectivity, immune escape and vaccines activity

Chakraborty, C., Bhattacharya, M., & Sharma, A. R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2270 · Cited by 111 · see citing works

Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function

Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Grüning, B. A., Shank, S. D., Weaver, S., MacLean, O. A., Orton, R. J., Lemey, P., et al. (2022) · Molecular Biology and Evolution · doi:10.1093/molbev/msac061 · Cited by 124 · see citing works

SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance

Guo, Y., Han, J., Zhang, Y., He, J., Yu, W., Zhang, X., Wu, J., Zhang, S., Kong, Y., Guo, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877101 · Cited by 116 · see citing works

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 141 · see citing works

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

Chen, E. C., Gilchuk, P., Zost, S. J., Suryadevara, N., Winkler, E. S., Cabel, C. R., Binshtein, E., Chen, R. E., Sutton, R. E., Rodriguez, J. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109604 · Cited by 76 · see citing works

Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding

Mannar, D., Saville, J. W., Zhu, X. Q., Srivastava, S. S., Berezuk, A., Zhou, S., Tuttle, K. S., Kim, A., Li, W., Dimitrov, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110156 · Cited by 88 · see citing works

The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape

Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · doi:10.1101/2021.02.23.21252268 · Cited by 291 · see citing works

Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants

Zhang, L., Dutta, S., Xiong, S., Chan, M. C., Chan, K. K., Fan, T. M., Bailey, K. L., Lindeblad, M. O., Cooper, L. M., Rong, L., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00965-6 · Cited by 85 · see citing works

Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM

Wang, Y., Xu, C., Wang, Y., Qin, H., Zhang, C., Li, Z., Xu, S., Zuo, Q., Liu, C., Huang, Z. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27350-0 · Cited by 83 · see citing works

Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

Hurlburt, N. K., Homad, L. J., Sinha, I. R., Jennewein, M. F., MacCamy, A. J., Wan, Y.-H., Boonyaratanakornkit, J. B., Sholukh, A. M., Jackson, A. M., Zhou, P.-P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03262-7 · Cited by 77 · see citing works

Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain

Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75 · see citing works

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants

Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 76 · see citing works

Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain

Smith, K. N., Clark, S. A., Shankar, S., Pan, J., Clark, L. E., Yang, P., Coscia, A., McKay, L. G. A., Varnum, H., Brusic, V., et al. (2022) · Science · doi:10.1126/science.abl6251 · Cited by 77 · see citing works

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Reincke, S. M., Yuan, M., Kornau, H., Corman, V. M., van Hoof, S., Sánchez-Sendín, E., Ramberger, M., Yu, W., Hua, Y., Tien, H. J., et al. (2022) · Science · doi:10.1126/science.abm5835 · Cited by 73 · see citing works

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine

Melo-González, F., Soto, J. A., González, L. A., Fernández, J. O., Duarte, L. F., Schultz, B. M., Gálvez, N. M. S., Pacheco, G. A., Ríos, M., Vázquez, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747830 · Cited by 78 · see citing works

SARS-CoV-2 Delta and Omicron variants evade population antibody response by mutations in a single spike epitope

He, P., Liu, B., Gao, X., Yan, Q., Pei, R., Sun, J., Chen, Q., Hou, R., Li, Z., Zhang, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01235-4 · Cited by 78 · see citing works

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

Zhao, F., Zai, X., Zhang, Z., Xu, J., & Chen, W. (2022) · npj Vaccines · doi:10.1038/s41541-022-00597-4 · Cited by 81 · see citing works

COVID-19 Vaccines: Adenoviral Vectors

Jacob-Dolan, C., & Barouch, D. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-012621-102252 · Cited by 76 · see citing works

A broad and potent neutralization epitope in SARS-related coronaviruses

Yuan, M., Zhu, X., He, W., Zhou, P.-P., Kaku, C. I., Capozzola, T., Zhu, C. Y., Yu, X., Liu, H., Yu, W., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2205784119 · Cited by 74 · see citing works

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

Planchais, C., Fernández, I., Bruel, T., de Melo, G. D., Prot, M., Beretta, M., Guardado‐Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backović, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220638 · Cited by 69 · see citing works

Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion

Xue, S., Han, Y., Wu, F., & Wang, Q. (2024) · Protein & Cell · doi:10.1093/procel/pwae007 · Cited by 72 · see citing works

Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain

Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100527 · Cited by 78 · see citing works

SARS-CoV-2 variants, immune escape, and countermeasures

Zhang, Y., Zhang, H. C., & Zhang, W. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0906-x · Cited by 70 · see citing works

Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses

Hills, R. A., Tan, T. K., Cohen, A. A., Keeffe, J. R., Keeble, A. H., Gnanapragasam, P. N. P., Storm, K. N., Rorick, A. V., West, A. P., Hill, M. L., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01655-9 · Cited by 79 · see citing works

A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Liu, H., Yuan, M., Huang, D.-L., Bangaru, S., Zhao, F.-Z., Lee, C. D., Peng, L., Barman, S., Zhu, X.-Y., Nemazee, D., et al. (2021) · Cell Host and Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 46 · see citing works

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain

Wheatley, A. K., Pymm, P., Esterbauer, R., Dietrich, M. H., Lee, W. S., Drew, D. R., Kelly, H. G., Chan, L., Mordant, F. L., Black, K. A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109822 · Cited by 60 · see citing works

ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology

Gawish, R., Starkl, P. M., Pimenov, L., Hladik, A., Lakovits, K., Oberndorfer, F., Cronin, S. J., Ohradanova‐Repic, A., Wirnsberger, G., Agerer, B., et al. (2022) · eLife · doi:10.7554/elife.74623 · Cited by 58 · see citing works

Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses

He, W., Musharrafieh, R. G., Song, G., Dueker, K., Tse, L. V., Martinez, D. R., Schäfer, A., Callaghan, S., Yong, P., Beutler, N., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01222-1 · Cited by 57 · see citing works

Catching COVID: Engineering Peptide-Modified Surface-Enhanced Raman Spectroscopy Sensors for SARS-CoV-2

Payne, T. D., Klawa, S. J., Jian, T., Kim, S. H., Papanikolas, M., Freeman, R., & Schultz, Z. D. (2021) · ACS Sensors · doi:10.1021/acssensors.1c01344 · Cited by 61 · see citing works

Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers

Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 55 · see citing works

Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants

Monteil, V., Eaton, B., Postnikova, E. N., Murphy, M. J., Braunsfeld, B., Crozier, I., Kricek, F., Niederhöfer, J., Schwarzböck, A., Breid, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115230 · Cited by 53 · see citing works

Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses

Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 58 · see citing works

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

Fang, Z., Peng, L., Filler, R. B., Suzuki, K., McNamara, A., Lin, Q., Renauer, P. A., Yang, L., Menasché, B. L., Sanchez, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30878-4 · Cited by 54 · see citing works

Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis

Kumar, R., Srivastava, Y., Muthuramalingam, P., Singh, S. K., Verma, G., Tiwari, S., Tandel, N., Beura, S. K., Panigrahi, A. R., Maji, S., et al. (2023) · Viruses · doi:10.3390/v15040856 · Cited by 55 · see citing works

Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants

Bai, C., Wang, J., Chen, G., Zhang, H., An, K., Xu, P., Du, Y., Ye, R. D., Saha, A., Zhang, A., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07965 · Cited by 51 · see citing works

Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern

Pondé, R. A. D. A. (2022) · Virology · doi:10.1016/j.virol.2022.05.003 · Cited by 52 · see citing works

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape

Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 53 · see citing works

SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people

Narowski, T. M., Raphel, K., Adams, L. E., Huang, J., Vielot, N. A., Jadi, R., de Silva, A. M., Baric, R. S., Lafleur, J., & Premkumar, L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110336 · Cited by 51 · see citing works

Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant

Sokal, A., Broketa, M., Barba-Spaeth, G., Meola, A., Fernández, I., Fourati, S., Azzaoui, I., de La Selle, A., Vandenberghe, A., Roeser, A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.002 · Cited by 50 · see citing works

An antibody from single human V H -rearranging mouse neutralizes all SARS-CoV-2 variants through BA.5 by inhibiting membrane fusion

Luo, S., Zhang, J., Kreutzberger, A. J. B., Eaton, A., Edwards, R. J., Jing, C., Dai, H., Sempowski, G. D., Cronin, K. D., Parks, R., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.add5446 · Cited by 51 · see citing works

Protective neutralizing epitopes in SARS‐CoV‐2

Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 46 · see citing works

Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants

Ju, B., Zhang, Q., Wang, Z., Aw, Z. Q., Chen, P., Zhou, B., Wang, R., Ge, X., Lv, Q., Cheng, L., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01449-6 · Cited by 49 · see citing works

Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19

Ameratunga, R., Longhurst, H. J., Steele, R. H., Lehnert, K., Leung, E. Y., Brooks, A. E. S., & Woon, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.019 · Cited by 48 · see citing works

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination

Chen, L., Lu, L., Choi, C. Y.-K., Cai, J., Tsoi, H., Chu, A. W., Ip, J. D., Chan, W.-M., Zhang, R., Zhang, X., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab656 · Cited by 48 · see citing works

Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern

Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 46 · see citing works

Characterization of SARS-CoV-2 Omicron spike RBD reveals significantly decreased stability, severe evasion of neutralizing-antibody recognition but unaffected engagement by decoy ACE2 modified for enhanced RBD binding

Lin, S., Chen, Z., Zhang, X., Wen, A., Yuan, X., Yu, C., Yang, J., He, B., Cao, Y., & Lu, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00914-2 · Cited by 47 · see citing works

Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron

Wang, L., Møhlenberg, M., Wang, P., & Zhou, H. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.001 · Cited by 45 · see citing works

Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview

Mehra, R., & Kepp, K. P. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00433 · Cited by 45 · see citing works

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Peng, L., Hu, Y., Mankowski, M. C., Ren, P., Chen, R. E., Wei, J., Zhao, M., Li, T., Tripler, T. N., Ye, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29288-3 · Cited by 43 · see citing works

Thiol-based chemical probes exhibit antiviral activity against SARS-CoV-2 via allosteric disulfide disruption in the spike glycoprotein

Shi, Y., Zeida, A., Edwards, C. E., Mallory, M. L., Sastre, S., Machado, M. R., Pickles, R. J., Fu, L. L., Liu, K., Yang, J. H., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120419119 · Cited by 43 · see citing works

Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera

Rathnasinghe, R., Jangra, S., Ye, C., Čupić, A., Singh, G., Martínez‐Romero, C., Mulder, L. C. F., Kehrer, T., Yildiz, S., Choi, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30763-0 · Cited by 41 · see citing works

Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses

Dijokaite-Guraliuc, A., Das, R., Zhou, D., Ginn, H. M., Liu, C., Duyvesteyn, H. M. E., Huo, J., Nutalai, R., Supasa, P., Selvaraj, M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112271 · Cited by 45 · see citing works

SARS-CoV-2 Spike Protein Mutations and Escape from Antibodies: A Computational Model of Epitope Loss in Variants of Concern

Triveri, A., Serapian, S. A., Marchetti, F., Doria, F., Pavoni, S., Cinquini, F., Moroni, E., Rasola, A., Frigerio, F., & Colombo, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00857 · Cited by 38 · see citing works

Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor

Capraz, T., Kienzl, N. F., Laurent, E., Perthold, J. W., Föderl-Höbenreich, E., Grünwald‐Gruber, C., Maresch, D., Monteil, V., Niederhöfer, J., Wirnsberger, G., et al. (2021) · eLife · doi:10.7554/elife.73641 · Cited by 41 · see citing works

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment

Focosi, D., McConnell, S. A., Sullivan, D. J., & Casadevall, A. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100991 · Cited by 39 · see citing works

Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)

Trimpert, J., Adler, J. M., Eschke, K., Abdelgawad, A., Firsching, T. C., Ebert, N., Thao, T. T. N., Gruber, A. D., Thiel, V., Osterrieder, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abk0172 · Cited by 41 · see citing works

A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2Preprint

Wang, K., Cao, Y., Zhou, Y., Wu, J., Jia, Z., Hu, Y., Yisimayi, A., Fu, W., Wang, L., Liu, P., et al. (2021) · medRxiv · doi:10.1101/2021.09.02.21261735 · Cited by 38 · see citing works

Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike functionPreprint

Martin, D. P., Lytras, S., Lucaci, A. G., Maier, W., Grüning, B. A., Shank, S. D., Weaver, S., MacLean, O. A., Orton, R. J., Lemey, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.14.476382 · Cited by 40 · see citing works

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Strohl, W. R., Ku, Z., An, Z., Carroll, S. F., Keyt, B. A., & Strohl, L. M. (2022) · BioDrugs · doi:10.1007/s40259-022-00529-7 · Cited by 34 · see citing works

Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis

Zhang, Z., Zhang, J., & Wang, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.952916 · Cited by 37 · see citing works

The Rapid Assessment of Aggregated Wastewater Samples for Genomic Surveillance of SARS-CoV-2 on a City-Wide Scale

Fuqua, J. L., Rouchka, E. C., Waigel, S., Sokoloski, K. J., Chung, D., Zacharias, W., Zhang, M., Chariker, J. H., Talley, D., Santisteban, I. C., et al. (2021) · Pathogens · doi:10.3390/pathogens10101271 · Cited by 37 · see citing works

Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies

Huang, Q., Han, X., & Yan, J. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125348 · Cited by 36 · see citing works

Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses

Yin, V. C., Lai, S.-H., Caniels, T., Brouwer, P., Brinkkemper, M., Aldon, Y., Liu, H., Yuan, M., Wilson, I. A., Sanders, R., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00804 · Cited by 32 · see citing works

Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1

Windsor, I. W., Tong, P., Lavidor, O., Moghaddam, A. S., McKay, L. G. A., Gautam, A. K., Chen, Y., MacDonald, E. A., Yoo, D. K., Griffths, A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo3425 · Cited by 36 · see citing works

The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscapePreprint

Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · PubMed · doi:10.34944/dspace/7022 · Cited by 49 · see citing works

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint

Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134 · see citing works

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

Torres, J. L., Ozorowski, G., Andreano, E., Liu, H., Copps, J., Piccini, G., Donnici, L., Conti, M., Planchais, C., Planas, D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120976119 · Cited by 33 · see citing works

Rational Development of Hypervalent Glycan Shield‐Binding Nanoparticles with Broad‐Spectrum Inhibition against Fatal Viruses Including SARS‐CoV‐2 Variants

Li, Y., Xu, S., Ye, Q., Chi, H., Guo, Z., Chen, J., Wu, M. L., Fan, B., Li, B., Qin, C., et al. (2022) · Advanced Science · doi:10.1002/advs.202202689 · Cited by 35 · see citing works

Insights into SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival

Luan, B., & Huynh, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00311 · Cited by 58 · see citing works

Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations

Wu, L., Peng, C., Yang, Y., Shi, Y., Zhou, L., Xu, Z., & Zhu, W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab383 · Cited by 26 · see citing works

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion

Augusto, G. S., Mohsen, M. O., Zinkhan, S., Liu, X., Vogel, M., & Bachmann, M. F. (2021) · Allergy · doi:10.1111/all.15065 · Cited by 83 · see citing works

Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.

Wahid, M., Jawed, A., Mandal, R. K., Dailah, H. G., Janahi, E. M. A., Dhama, K., Somvanshi, P., & Haque, S. (2021) · PubMed · doi:10.26355/eurrev_202109_26805 · Cited by 28 · see citing works

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants

Xu, H., Wang, B., Zhao, T.-N., Liang, Z., Peng, T., Song, X., Wu, J., Wang, Y., & Su, X. (2021) · Cell Research · doi:10.1038/s41422-021-00554-1 · Cited by 13 · see citing works